Strata Critical MedicalSRTA -3.68%70 Return-on-Tangible-Equity is 5.86% as of Mar. 2026. GuruFocus rates SRTA with a GF Score™ of 70/100 and a GF Value™ of $4.47 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Strata Critical Medical ranks better than 76.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Strata Critical Medical's annualized net income for the quarter that ended in Mar. 2026 was $8.6 Mil. Strata Critical Medical's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $147.1 Mil. Therefore, Strata Critical Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.86%.
The historical rank and industry rank for Strata Critical Medical's Return-on-Tangible-Equity or its related term are showing as below:
SRTA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -96.33 Med: -21.87 Max: 30.43
Current: 30.43
During the past 7 years, Strata Critical Medical's highest Return-on-Tangible-Equity was 30.43%. The lowest was -96.33%. And the median was -21.87%.
SRTA's Return-on-Tangible-Equity is ranked better than 76.86% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs SRTA: 30.43
Strata Critical Medical (NAS:SRTA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Strata Critical Medical Return-on-Tangible-Equity Related Terms
Strata Critical Medical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Strata Critical Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Critical Medical Return-on-Tangible-Equity Chart
SRTA vs CYH, CCRN, AUNA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Strata Critical Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.86% mean?
Strata Critical Medical (SRTA) has a Return-on-Tangible-Equity of 5.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Strata Critical Medical and its competitors. According to the industry distribution chart, Strata Critical Medical ranks #134 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 23.1%.
Is Strata Critical Medical's Return-on-Tangible-Equity too high?
Strata Critical Medical's current Return-on-Tangible-Equity is 5.86%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.13. Strata Critical Medical's value of 5.86% is 42.2% below this industry median. Based on the distribution chart, Strata Critical Medical ranks #134 out of 579 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Strata Critical Medical has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's Return-on-Tangible-Equity compare to CYH and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Strata Critical Medical ranks #134 out of 579 companies for Return-on-Tangible-Equity. This places Strata Critical Medical in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.13. Strata Critical Medical's value of 5.86% is 42.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Critical Medical's current Return-on-Tangible-Equity of 5.86% is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Strata Critical Medical and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Critical Medical's current Return-on-Tangible-Equity is 5.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.47, compared to a current price of $5.24 — trading 17.2% above its estimated fair value. The current Return-on-Tangible-Equity is 5.86% and 42.2% below the Healthcare Providers & Services industry median of 10.13. Strata Critical Medical's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current Return-on-Tangible-Equity is 5.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $5.24 is trading 17.2% above its estimated GF Value™ of $4.47.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
Return-on-Tangible-Equity: 5.86%
GF Value™: $4.47 vs. price of $5.24 (17.2% above fair value)
Industry Position: 42.2% below the Healthcare Providers & Services median (#134 of 579)
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
70GF Score
Get the complete analysis for SRTA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
